Does COVID-19 affect cancer patients receiving immunotherapy more severely?

Cancer patients are known to face a risk of more severe COVID-19, the illness caused by the novel coronavirus and a higher risk of death. However, until now there has been no guidance on how certain cancer treatments, such as immunotherapies, affect these risks.
Some concerns had been raised about the effects of immune checkpoint inhibitors, the most commonly used type of immunotherapy in recent years, on COVID-19 treatment. However, a new study published on 12 May found that, in patients with lung cancer, immunotherapy that blocks PD-1 and activates the immune system against cancer did not affect the course of COVID-19. The study included 69 patients receiving outpatient treatment for lung cancer who were diagnosed with COVID-19 in March and April.
We generally do not think that immune checkpoint inhibitors suppress the immune system and make patients more susceptible to infections. However, oncology professionals had wondered about some side effects that cancer patients receiving immunotherapy might develop and whether these could affect their ability to fight infections such as coronavirus. We can say that this study has reduced our concerns.
One hypothesis proposed to explain the situation is that the medicines might trigger the excessive immune response observed in some patients and lead to severe illness.
The discovery of immune checkpoint inhibitors and their benefits in treatment have been revolutionary. Metastatic lung cancers are among the conditions in which they produce favorable results, providing a 20-25% survival or longer-life benefit; in other words, one in every 5 patients with advanced lung cancer lives for more than 5 years with immunotherapy. However, cytokine release syndrome, often observed in hospitalized patients with severe COVID-19, can also occur with treatments using immune checkpoint inhibitors. The similarities between these two situations are concerning. Conditions that impair lung function can have very serious consequences.
The study analyzed patients grouped according to whether they had received their most recent immunotherapy dose within 6 months or within 6 weeks, or their first dose within the first 3 months. No difference in COVID-19 severity was observed between the groups.
However, the small number of participants should also be emphasized. There may be many differences in their treatment histories and in the treatments they received for coronavirus. In this situation, it is very difficult to reach a firm conclusion without a homogeneous study group. Other factors alongside lung cancer, such as heart disease, diabetes, high blood pressure and smoking, are also known to increase the risk of death in patients with both lung cancer and COVID-19.
Reports from China show a higher mortality rate among cancer patients diagnosed with COVID-19 (5.6%) than the overall mortality rate (3%). A similar pattern is seen in people with diabetes (7.3%) and chronic respiratory disease (6.3%). These COVID-19 rates are concerning for people with additional illnesses. We know that our patients have weaker immune systems. Therefore, cancer patients with lung cancer who are diagnosed with COVID-19 should be hospitalized for monitoring.
Commentary - Summary
Although this was a small study with limitations, its findings addressed some uncertainties and indicated that using these treatments during the pandemic might not pose a problem. However, larger, more detailed studies are needed before firm conclusions can be drawn. Treatment using immune checkpoint inhibitors is not the only option used for cancer patients. Radiotherapy and targeted cancer medicines called tyrosine kinase inhibitors are also used and may cause lung problems. Therefore, many studies are being conducted to investigate the effects of different cancer treatments on COVID-19 severity and mortality.
- ALL OUR CORONAVIRUS ARTICLES -
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.